FDA Determines Regulatory Review Period for Neurontin Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Neurontin, a prescription medication, in accordance with federal regulations. This decision was prompted by a formal application submitted to the US Patent and Trademark Office (USPTO) for an extension of the patent, which covers the human drug product Neurontin.